KDM1A

Across TCGA pan-cancer cohorts, KDM1A Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated KDM1A data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher KDM1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KDM1A expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

SARC, BLCA, and PRAD are the cancer types where KDM1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.101	0.632	.011	12	view →
BLCA	OS	Median	IV	1.000	0.242	.015	7	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SCLC	DFS	Median	All	0.192	0.793	.017	6	view →
COAD	OS	Median	II,III,IV	0.176	0.655	.016	4	view →
SKCM	DFS	Median	All	0.379	0.616	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

KDM1A–SARC (DFS)

Open the SARC breakdown →